Human Growth Hormone Injections Annual Sales in China Less Than $1 Billion

---

Researched by Industrial Info Resources (Sugar Land, Texas)--At present, China's domestic human growth hormone (hGH) mainly includes water and powder injections. Aqueous injection formulations have certain advantages in terms of drug activity and stability, and they are the main variety on the market. However, the common problem of the two forms of hGH is a shorter half-life and higher injection frequency. Long-acting hGH can solve this problem.

In 2020, the annual sales of hGH in China was less than 6 billion yuan (US$940 million), of which the long-acting hGH was only 600 million yuan (US$94 million).

IIR is now tracking 42 active injections projects in China, worth US$3.15 billion. The company with the largest expenditures is Zhejiang Huahai Pharmaceutical Company Limited, which has planned more than $470.2 million in injections project investments. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharma-Biotech Project Database can click here for related project reports.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.